Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kui Liu, Quan-Zhen Li, Angelica M. Delgado-Vega, Anna-Karin Abelson, Elena Sánchez, Jennifer A. Kelly, Li Li, Yang Liu, Jinchun Zhou, Mei Yan, Qiu Ye, Shenxi Liu, Chun Xie, Xin J. Zhou, Sharon A. Chung, Bernardo Pons-Estel, Torsten Witte, Enrique de Ramón, Sang-Cheol Bae, Nadia Barizzone, Gian Domenico Sebastiani, Joan T. Merrill, Peter K. Gregersen, Gary G. Gilkeson, Robert P. Kimberly, Timothy J. Vyse, Il Kim, Sandra D’Alfonso, Javier Martin, John B. Harley, Lindsey A. Criswell, The Profile Study Group, The Italian Collaborative Group, The German Collaborative Group, The Spanish Collaborative Group, The Argentinian Collaborative Group, The SLEGEN Consortium, Edward K. Wakeland, Marta E. Alarcón-Riquelme, Chandra Mohan
Published in Volume 119, Issue 4
J Clin Invest. 2009; 119(4):911–923 doi:10.1172/JCI36728
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
Impact of BK receptor blockade or activation on the severity of AIGN.

BALB/c mice were treated with BK receptor antagonists (B1 receptor blocker H158 [B1-R] or B2 receptor blocker H157) or PBS vehicle alone as placebo (None), using osmotic pumps, for the 14-day duration of an anti-GBM challenge and phenotyped for proteinuria (A), azotemia (B), and GN (C, B1-R blocked; and D, B2-R blocked). Original magnification, ×400. (E) Conversely, the administration of BK into 129/SvJ mice using osmotic pumps ameliorated disease after anti-GBM challenge, compared with mice treated with vehicle placebo. In A, B, and E, each dot represents data from a single mouse, and the horizontal bars denote arithmetic group means.